Margaret M. Wasilewski

Internal Medicine

67 Old Kings Hwy
Ogunquit, ME 03907

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4 publications

Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100, a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, double-blind study in healthy adults.

Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100, a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, double-blind study in healthy adults.

Journal: Headache

Published: December 20, 2023

Intravenous arylsulfatase A in metachromatic leukodystrophy: a phase 1/2 study.

Intravenous arylsulfatase A in metachromatic leukodystrophy: a phase 1/2 study.

Journal: Annals of clinical and translational neurology

Published: September 16, 2020

Safety of intrathecal delivery of recombinant human arylsulfatase A in children with metachromatic leukodystrophy: Results from a phase 1/2 clinical trial.

Safety of intrathecal delivery of recombinant human arylsulfatase A in children with metachromatic leukodystrophy: Results from a phase 1/2 clinical trial.

Journal: Molecular genetics and metabolism

Published: April 30, 2020

Pharmacokinetic Modeling of Intrathecally Administered Recombinant Human Arylsulfatase A (TAK-611) in Children With Metachromatic Leukodystrophy.

Pharmacokinetic Modeling of Intrathecally Administered Recombinant Human Arylsulfatase A (TAK-611) in Children With Metachromatic Leukodystrophy.

Journal: Clinical pharmacology and therapeutics

Published: July 19, 2019

Showing 1-4 of 4

Last Updated: 09/26/2026